688317 之江生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-0.767-0.982-3.416-3.41118.941
总资产报酬率 ROA (%)-0.683-0.908-3.242-3.10416.898
投入资产回报率 ROIC (%)-0.702-0.938-3.393-3.36818.639

边际利润分析
销售毛利率 (%)68.85864.15360.94665.12351.645
营业利润率 (%)-92.786-38.115-81.536-54.49539.005
息税前利润/营业总收入 (%)-57.123-62.216-155.391-88.00234.123
净利润/营业总收入 (%)-100.358-27.478-71.347-49.88732.682

收益指标分析
经营活动净收益/利润总额(%)135.374157.938-12.316-7.35494.693
价值变动净收益/利润总额(%)-8.726-14.677-0.0380.0000.000
营业外收支净额/利润总额(%)1.302-12.9593.2584.555-0.652

偿债能力分析
流动比率 (X)25.18623.59120.10813.3837.463
速动比率 (X)24.76023.23119.71512.3116.501
资产负债率 (%)10.90311.0254.0396.11811.456
带息债务/全部投入资本 (%)8.3298.3090.3590.4991.184
股东权益/带息债务 (%)1,099.1931,102.11027,694.86519,878.5148,310.048
股东权益/负债合计 (%)817.212807.0472,376.0671,534.554772.931
利息保障倍数 (X)-1.5492.1852.1852.847-7.370

营运能力分析
应收账款周转天数 (天)108.483124.398158.301216.34134.287
存货周转天数 (天)539.395414.128802.2591,425.308128.576